The Anti-Amyloid Therapy Monitoring (ATM) study is examining how people respond to anti-amyloid therapies for Alzheimer’s disease. The goal is to find better ways to monitor treatment, identifying who benefits most and who may be at higher risk of side effects.
Who can join?
You may be eligible if you:
- Have been diagnosed with mild cognitive impairment or mild Alzheimer’s disease who are prescribed anti-amyloid therapy by their treating physician
- Are at or before their 5th lecanemab infusion or 3rd donanemab infusion
- Are receiving infusions at the Hospital of the University of Pennsylvania (3400 Spruce St.)
What does participation involve?
This study offers different levels of involvement depending on your comfort and interest:
Core Study
-
Blood draws during infusion visits
-
Memory and thinking games on your smartphone (optional)
-
Compensation: $50 total
Advanced Study
-
Everything in the Core Study, plus:
-
MRI scans to monitor brain changes
-
Cognitive testing
-
Compensation: $200 total
Interested or have questions?
Contact Danielle Hing at danielle.hing@pennmedicine.upenn.edu